Recombinant VSV as a platform for rabies vaccine development: Enhancing immunogenicity and safety

Haochen Zhao

doi:10.62051/g3v8bs44

Authors

Haochen Zhao

DOI:

https://doi.org/10.62051/g3v8bs44

Keywords:

Rabies Vaccine; Recombinant virus; Oral Vaccine; Wildlife Immunization; Long-term Immunity.

Abstract

The research investigates the possibility of development of a recombinant vesicular stomatitis virus (VSV) expressing the rabies virus glycoprotein as a novel rabies vaccine. The recombinant VSV can show robust immunogenicity, eliciting strong virus-neutralizing antibody responses in both mice and dogs. The oral vaccine formulation proved stable in simulated gastric conditions and induced immune responses comparable to intramuscular injection. Long-term immunity studies indicated high antibody levels and protection against rabies virus challenge at six months and one-year post-immunization, suggesting potential for durable immunity, particularly in dogs. Toxicity studies can be used to analyze adverse effects, confirming the vaccine’s safety. The potential for the recombinant VSV vaccine to induce mucosal immunity and spread through social behaviours in wildlife populations presents a promising approach for rabies control. However, challenges such as ensuring genetic stability and evaluating environmental impacts must be addressed. This research highlights the recombinant VSV-based vaccine’s promise as an effective, safe, and potentially self-disseminating tool for rabies prevention, with implications for both human and veterinary applications.

Downloads

Download data is not yet available.

References

[1] C. E. Rupprecht, C. A. Hanlon, T. Hemachudha, Rabies re-examined. The Lancet infectious diseases 2(6) (2002) 327-343

[2] J. D. Blanton, R. M. Wallace, The ancient curse: rabies. Infections of Leisure (2016) 235-250

[3] World Health Organization. Rabies vaccines: WHO position paper, April 2018–Recommendations. Vaccine 36(37) (2018) 5500-5503

[4] A. C. Jackson, Rabies: a medical perspective. Revue scientifique et technique (International Office of Epizootics) 37(2) (2018) 569-580

[5] World Health Organization. Rabies epidemiology and burden of disease. WHO Rabies Bulletin (2020)

[6] G. Wu, D. Selden, A. R. Fooks, et al. Inactivation of rabies virus. Journal of Virological Methods 243 (2017) 109-112

[7] A. R. Fooks, A. C. Banyard, D. L. Horton, et al. Current status of rabies and prospects for elimination. The Lancet 384(9951) (2014) 1389-1399

[8] C. E. Rupprecht, D. Briggs, C. M. Brown, et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep 59(RR-2) (2010) 1-9

[9] G. Liu, W. Cao, A. Salawudeen, et al. Vesicular stomatitis virus: from agricultural pathogen to vaccine vector. Pathogens 10(9) (2021) 1092

[10] X. Xue, Z. Yu, H. Jin, et al. Recombinant adenovirus expressing vesicular stomatitis virus G proteins induce both humoral and cell-mediated immune responses in mice and goats. BMC Veterinary Research 17 (2021) 1-9

[11] A. Marzi, F. Engelmann, F. Feldmann, et al. Antibodies are necessary for rVSV/ZEBOV-GP–mediated protection against lethal Ebola virus challenge in nonhuman primates. Proceedings of the National Academy of Sciences 110(5) (2013) 1893-1898

[12] A. M. Henao-Restrepo, A. Camacho, I. M. Longini, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). The Lancet 389(10068) (2017) 505-518

[13] K. Kolell, J. Padilla-Zamudio, B. Schuchhardt, et al. Virus production in Vero cells using a serum-free medium. In Cell Technology for Cell Products: Proceedings of the 19th ESACT Meeting, Harrogate, UK, June 5-8, 2005 (pp. 583-585). Dordrecht: Springer Netherlands (2007)

[14] D. Slate, T. P. Algeo, K. M. Nelson, et al. Oral rabies vaccination in North America: opportunities, complexities, and challenges. PLoS neglected tropical diseases 3(12) (2009) e549

[15] F. Cliquet, C. Freuling, M. Smreczak, et al. Development of harmonised schemes for monitoring and reporting of rabies in animals in the European Union. EFSA Supporting Publications 7(7) (2010) 67E

[16] J. Maki, A. L. Guiot, M. Aubert, et al. Oral vaccination of wildlife using a vaccinia–rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG®): a global review. Veterinary research 4 (2017) 1-26.